Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Cost-effectiveness Analysis
100%
Cost-effectiveness
100%
Hypertension Management
100%
Clinical Benefit
100%
Developing Countries
100%
Antihypertensive Therapy
100%
Treatment Efficacy
50%
Quality of Life
50%
Healthcare
50%
Blood Pressure
50%
Cognitive Impairment
50%
Myocardial Infarction
50%
Heart Failure
50%
Quality of Life Improvement
50%
Developed Countries
50%
Economic Benefits
50%
Renal Damage
50%
Health Gains
50%
Life Impairments
50%
Failure Damage
50%
Ocular Trauma
50%
Medicine and Dentistry
Cost-Effectiveness Analysis
100%
Hypertension
100%
Quality of Life
66%
Antihypertensive Therapy
66%
Health Care
33%
Apoplexy
33%
Cognitive Defect
33%
Blood Pressure
33%
Myocardial Infarction
33%
Congestive Heart Failure
33%
Kidney Injury
33%
Asymptomatic Disease
33%
Eye Injury
33%
Pharmacology, Toxicology and Pharmaceutical Science
Antihypertensive Agent
100%
Hypertension
100%
Cerebrovascular Accident
50%
Heart Infarction
50%
Congestive Heart Failure
50%
Kidney Injury
50%
Asymptomatic Disease
50%
Cognitive Defect
50%
Eye Injury
50%
Psychology
Quality of Life
100%
Hypertension
100%
Blood Pressure
50%
Healthcare
50%
Cognitive Impairment
50%
Myocardial Infarction
50%